Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MorphoSys AG

www.morphosys.com

Latest From MorphoSys AG

MorphoSys: A European Champion Crossing The Biopharma Rubicon

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

BioPharmaceutical C-Suite Speaks

New CEO At MorphoSys Seeking Partner For ‘CAR-T Killer’ Lymphoma Drug

Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.

Commercial Strategy

Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options

Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.

Commercial Deals

Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda

The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • MorphoSys AG
  • Senior Management
  • Simon E Moroney, PhD, CEO
    Jens Holstein, CFO
    Malte Peters, MD, Chief Dev. Officer
    Markus Enzelberger , PhD, CSO
  • Contact Info
  • MorphoSys AG
    Phone: (49) 89 899 27 0
    Semmelweisstr. 7
    Planegg, 82152
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register